ERBB2 and breast cancer: Furthermore, a subgroup analysis of the DESTINY-Breast03 trial comparing T-DM1 to TDXd in patients with HER2-positive breast cancer demonstrated a clinical inferiority of T-DM1 versus TDXd [82].